Abstract
The neuropeptide oxytocin (OXT) has been identified as a potential therapeutic intervention for ASD due to its involvement in social bonding and affiliative behaviors. The present study aimed to assess the effectiveness and safety of intranasal administration of OXT in preclinical and clinical investigations related to ASD. The random-effects meta-analysis method evaluated the combined effect sizes, heterogeneity, and publication bias. Additionally, subgroup analyses were conducted to investigate potential moderators. We confirmed 54 preclinical, animal model, and clinical trials on 2593 cases with ASD through systematic search in PubMed, Web of Science, CNKI, Scopus, and Cochrane library databases from 1980 to 2023. The least-squares mean change of ABC-mSW was significantly lower in the OXT group than in Placebo (SMD, −1.45; 95% CI, −2.24, −0.66; P = 0.0003; I2 = 93%). The analysis showed significantly low OXT plasma concentration after intranasal OXT compared with placebo (SMD, 0.94; 95% CI, 0.48, 1.40; P < 0.0001; I2 = 82%). Our analysis showed only CGI improvement was significantly seen in patients with ASD receiving intranasal OXT compared with placebo (SMD, 0.07; 95% CI, 0.00, 0.14; P = 0.04; I2 = 0%). The meta-analysis suggests that the administration of intranasal OXT may have a positive impact on the behavior of individuals with ASD, particularly in terms of enhancing social and communicative abilities. Nevertheless, turning preclinical research discoveries into clinical applications poses a significant hurdle. Additional research is necessary to ascertain the most effective dose, delivery techniques, and long-term consequences to optimize the treatment efficacy and safety for individuals with ASD. Future research endeavors should aim to investigate the heterogeneity of ASD and the variability in responsiveness to interventions involving intranasal OXT.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abdollahifard, S. (2022). Intranasal oxytocin in autism spectrum disorder children and adolescents. Clinical Psychiatry, 8(8), 102–103. Available at: https://www.primescholars.com/clinical-psychiatry.html
Alsayouf, H. A., Talo, H., Biddappa, M. L., & De Los Reyes, E. (2021). Risperidone or aripiprazole can resolve autism core signs and symptoms in young children: Case Study. Children (Basel), 8(5). https://doi.org/10.3390/children8050318
Althaus, M., Groen, Y., Wijers, A. A., Noltes, H., Tucha, O., Sweep, F. C., et al. (2016). Do blood plasma levels of oxytocin moderate the effect of nasally administered oxytocin on social orienting in high-functioning male adults with autism spectrum disorder? Psychopharmacology, 233(14), 2737–2751. https://doi.org/10.1007/s00213-016-4339-1
Anagnostou, E., Soorya, L., Brian, J., Dupuis, A., Mankad, D., Smile, S., & Jacob, S. (2014). Intranasal oxytocin in the treatment of autism spectrum disorders: A review of literature and early safety and efficacy data in youth. Brain Research, 1580, 188–198. https://doi.org/10.1016/j.brainres.2014.01.049
Anagnostou, E., Soorya, L., Chaplin, W., Bartz, J., Halpern, D., Wasserman, S., et al. (2012). Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: A randomized controlled trial. Molecular Autism, 3(1), 16. https://doi.org/10.1186/2040-2392-3-16
Andari, E., Duhamel, J.-R., Zalla, T., Herbrecht, E., Leboyer, M., & Sirigu, A. (2010). Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proceedings of the National Academy of Sciences, 107(9), 4389–4394. https://doi.org/10.1073/pnas.0910249107
Andari, E., Richard, N., Leboyer, M., & Sirigu, A. (2016). Adaptive coding of the value of social cues with oxytocin, an fMRI study in autism spectrum disorder. Cortex, 76, 79–88. https://doi.org/10.1016/j.cortex.2015.12.010
Aoki, Y., Yahata, N., Watanabe, T., Takano, Y., Kawakubo, Y., Kuwabara, H., et al. (2014). Oxytocin improves behavioural and neural deficits in inferring others’ social emotions in autism. Brain, 137(11), 3073–3086. https://doi.org/10.1093/brain/awu231
Auyeung, B., Lombardo, M. V., Heinrichs, M., Chakrabarti, B., Sule, A., Deakin, J. B., et al. (2015). Oxytocin increases eye contact during a real-time, naturalistic social interaction in males with and without autism. Translational Psychiatry, 5(2), e507–e507. https://doi.org/10.1038/tp.2014.146
Bales, K. L., Solomon, M., Jacob, S., Crawley, J. N., Silverman, J. L., Larke, R. H., et al. (2014). Long-term exposure to intranasal oxytocin in a mouse autism model. Translational Psychiatry, 4(11), e480. https://doi.org/10.1038/tp.2014.117
Baribeau, D., Vorstman, J., & Anagnostou, E. (2022). Novel treatments in autism spectrum disorder. Current Opinion in Psychiatry, 35(2), 101–110. https://doi.org/10.1097/yco.0000000000000775
Bernaerts, S., Boets, B., Bosmans, G., Steyaert, J., & Alaerts, K. (2020). Behavioral effects of multiple-dose oxytocin treatment in autism: A randomized, placebo-controlled trial with long-term follow-up. Molecular Autism, 11(1), 6. https://doi.org/10.1186/s13229-020-0313-1
Booth, A. J., Rodgers, J. D., Volker, M. A., Lopata, C., & Thomeer, M. L. (2019). Psychometric characteristics of the DANVA-2 in high-functioning children with ASD. Journal of Autism and Developmental Disorders, 49(10), 4147–4158. https://doi.org/10.1007/s10803-019-04130-w
Bosch, O. J., & Young, L. J. (2018). Oxytocin and social relationships: From attachment to bond disruption. Current Topics in Behavioral Neurosciences, 35, 97–117. https://doi.org/10.1007/7854_2017_10
Bottema-Beutel, K., Crowley, S., Sandbank, M., & Woynaroski, T. G. (2021). Adverse event reporting in intervention research for young autistic children. Autism, 25(2), 322–335. https://doi.org/10.1177/1362361320965331
Braden, B. B., Pagni, B. A., Monahan, L., Walsh, M. J. M., Dixon, M. V., Delaney, S., et al. (2022). Quality of life in adults with autism spectrum disorder: Influence of age, sex, and a controlled, randomized mindfulness-based stress reduction pilot intervention. Quality of Life Research, 31(5), 1427–1440. https://doi.org/10.1007/s11136-021-03013-x
Busner, J., & Targum, S. D. (2007). The clinical global impressions scale: Applying a research tool in clinical practice. Psychiatry (Edgmont), 4(7), 28–37.
Cai, Q., Feng, L., & Yap, K. Z. (2018). Systematic review and meta-analysis of reported adverse events of long-term intranasal oxytocin treatment for autism spectrum disorder. Psychiatry and Clinical Neurosciences, 72(3), 140–151. https://doi.org/10.1111/pcn.12627
Chaxiong, P., Burrows, C., Botteron, K. N., Dager, S. R., Estes, A. M., Hazlett, H. C., et al. (2022). Relations of restricted and repetitive behaviors to social skills in toddlers with autism. Journal of Autism and Developmental Disorders, 52(4), 1423–1434. https://doi.org/10.1007/s10803-021-05014-8
Chen, X., Xu, Y., Li, B., Wu, X., Li, T., Wang, L., et al. (2021). Intranasal vasopressin modulates resting state brain activity across multiple neural systems: Evidence from a brain imaging machine learning study. Neuropharmacology, 190, 108561. https://doi.org/10.1016/j.neuropharm.2021.108561
Chung, S., Peters, J. M., Detyniecki, K., Tatum, W., Rabinowicz, A. L., & Carrazana, E. (2023). The nose has it: Opportunities and challenges for intranasal drug administration for neurologic conditions including seizure clusters. Epilepsy & Behavior Reports, 21, 100581. https://doi.org/10.1016/j.ebr.2022.100581
Cochran, D. M., Fallon, D., Hill, M., & Frazier, J. A. (2013). The role of oxytocin in psychiatric disorders: A review of biological and therapeutic research findings. Harvard Review of Psychiatry, 21(5), 219–247. https://doi.org/10.1097/HRP.0b013e3182a75b7d
Da Prato, L. C., Zayan, U., Abdallah, D., Point, V., Schaller, F., Pallesi-Pocachard, E., et al. (2022). Early life oxytocin treatment improves thermo-sensory reactivity and maternal behavior in neonates lacking the autism-associated gene Magel2. Neuropsychopharmacology, 47(11), 1901–1912. https://doi.org/10.1038/s41386-022-01313-5
Dadds, M. R., MacDonald, E., Cauchi, A., Williams, K., Levy, F., & Brennan, J. (2014). Nasal oxytocin for social deficits in childhood autism: A randomized controlled trial. Journal of Autism and Developmental Disorders, 44(3), 521–531. https://doi.org/10.1007/s10803-013-1899-3
Dai, Y., Zhang, L., Yu, J., Zhou, X., He, H., Ji, Y., et al. (2021). Improved symptoms following bumetanide treatment in children aged 3−6 years with autism spectrum disorder: A randomized, double-blind, placebo-controlled trial. Science Bulletin, 66(15), 1591–1598. https://doi.org/10.1016/j.scib.2021.01.008
Daniels, N., Moerkerke, M., Steyaert, J., Bamps, A., Debbaut, E., Prinsen, J., et al. (2023). Effects of multiple-dose intranasal oxytocin administration on social responsiveness in children with autism: A randomized, placebo-controlled trial. Molecular Autism, 14(1), 16. https://doi.org/10.1186/s13229-023-00546-5
Deng, G., Ai, H., Qin, L., Xu, J., Feng, C., & Xu, P. (2022). Dissociated modulations of intranasal vasopressin on prosocial learning between reward-seeking and punishment-avoidance. Psychological Medicine, 1–13. https://doi.org/10.1017/s0033291722002483
Domes, G., Heinrichs, M., Kumbier, E., Grossmann, A., Hauenstein, K., & Herpertz, S. C. (2013). Effects of intranasal oxytocin on the neural basis of face processing in autism spectrum disorder. Biological Psychiatry, 74(3), 164–171. https://doi.org/10.1016/j.biopsych.2013.02.007
Ebitz, R. B., Watson, K. K., & Platt, M. L. (2013). Oxytocin blunts social vigilance in the rhesus macaque. Proceedings of the National Academy of Sciences USA, 110(28), 11630–11635. https://doi.org/10.1073/pnas.1305230110
Fastman, J., Foss-Feig, J., Frank, Y., Halpern, D., Harony-Nicolas, H., Layton, C., et al. (2021). A randomized controlled trial of intranasal oxytocin in Phelan-McDermid syndrome. Molecular Autism, 12(1), 62. https://doi.org/10.1186/s13229-021-00459-1
Feldman, R., Weller, A., Zagoory-Sharon, O., & Levine, A. (2007). Evidence for a neuroendocrinological foundation of human affiliation: Plasma oxytocin levels across pregnancy and the postpartum period predict mother-infant bonding. Psychological Science, 18(11), 965–970. https://doi.org/10.1111/j.1467-9280.2007.02010.x
Feng, C., Qin, L., Luo, Y., & Xu, P. (2020). Intranasal vasopressin expedites dishonesty in women. Horm Behav, 126, 104843. https://doi.org/10.1016/j.yhbeh.2020.104843
Ferguson, J. N., Aldag, J. M., Insel, T. R., & Young, L. J. (2001). Oxytocin in the medial amygdala is essential for social recognition in the mouse. The Journal of Neuroscience, 21(20), 8278–8285. https://doi.org/10.1523/jneurosci.21-20-08278.2001
Finton, C. J., & Ophir, A. G. (2022). Developmental exposure to intranasal vasopressin impacts adult prairie vole spatial memory. Psychoneuroendocrinology, 141, 105750. https://doi.org/10.1016/j.psyneuen.2022.105750
Fowlie, G., Cohen, N., & Ming, X. (2018). The perturbance of microbiome and gut-brain axis in autism spectrum disorders. International Journal of Molecular Sciences, 19(8), 2251 Retrieved from https://www.mdpi.com/1422-0067/19/8/2251
Fukai, M., Hirosawa, T., Kikuchi, M., Ouchi, Y., Takahashi, T., Yoshimura, Y., et al. (2017). Oxytocin effects on emotional response to others’ faces via serotonin system in autism: A pilot study. Psychiatry Research: Neuroimaging, 267, 45–50. https://doi.org/10.1016/j.pscychresns.2017.06.015
Gabriels, R. L., Cuccaro, M. L., Hill, D. E., Ivers, B. J., & Goldson, E. (2005). Repetitive behaviors in autism: Relationships with associated clinical features. Research in Developmental Disabilities, 26(2), 169–181. https://doi.org/10.1016/j.ridd.2004.05.003
Geffen, Y., Horev, R., Perets, N., Marom, E., Danon, U., & Offen, D. (2020). Immuno-modulation and neuroprotection mediate the therapeutic effect of exosomes in mice model of autism. Cytotherapy, 22(5, Supplement), S49–S50. https://doi.org/10.1016/j.jcyt.2020.03.060
Gidal, B., & Detyniecki, K. (2022). Rescue therapies for seizure clusters: Pharmacology and target of treatments. Epilepsia, 63(S1), S34–S44. https://doi.org/10.1111/epi.17341
Glovinsky, D., Kalogeras, K. T., Kirch, D. G., Suddath, R., & Wyatt, R. J. (1994). Cerebrospinal fluid oxytocin concentration in schizophrenic patients does not differ from control subjects and is not changed by neuroleptic medication. Schizophrenia Research, 11(3), 273–276. https://doi.org/10.1016/0920-9964(94)90021-3
Gordon, I., Jack, A., Pretzsch, C. M., Vander Wyk, B., Leckman, J. F., Feldman, R., & Pelphrey, K. A. (2016). Intranasal oxytocin enhances connectivity in the neural circuitry supporting social motivation and social perception in children with autism. Scientific Reports, 6, 35054. https://doi.org/10.1038/srep35054
Gordon, I., Vander Wyk, B. C., Bennett, R. H., Cordeaux, C., Lucas, M. V., Eilbott, J. A., et al. (2013). Oxytocin enhances brain function in children with autism. Proceedings of the National Academy of Sciences USA, 110(52), 20953–20958. https://doi.org/10.1073/pnas.1312857110
Greene, R. K., Spanos, M., Alderman, C., Walsh, E., Bizzell, J., Mosner, M. G., et al. (2018). The effects of intranasal oxytocin on reward circuitry responses in children with autism spectrum disorder. Journal of Neurodevelopmental Disorders, 10(1), 12. https://doi.org/10.1186/s11689-018-9228-y
Guastella, A. J., Boulton, K. A., Whitehouse, A. J. O., Song, Y. J., Thapa, R., Gregory, S. G., et al. (2023). The effect of oxytocin nasal spray on social interaction in young children with autism: a randomized clinical trial. Molecular Psychiatry, 28(2), 834–842. https://doi.org/10.1038/s41380-022-01845-8
Guastella, A. J., Einfeld, S. L., Gray, K. M., Rinehart, N. J., Tonge, B. J., Lambert, T. J., & Hickie, I. B. (2010). Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biological Psychiatry, 67(7), 692–694. https://doi.org/10.1016/j.biopsych.2009.09.020
Guastella, A. J., Gray, K. M., Rinehart, N. J., Alvares, G. A., Tonge, B. J., Hickie, I. B., et al. (2015). The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: A randomized controlled trial. Journal of Child Psychology and Psychiatry, 56(4), 444–452. https://doi.org/10.1111/jcpp.12305
Guastella, A. J., Mitchell, P. B., & Dadds, M. R. (2008). Oxytocin increases gaze to the eye region of human faces. Biological Psychiatry, 63(1), 3–5. https://doi.org/10.1016/j.biopsych.2007.06.026
Hadjikhani, N., Galazka, M., Kenet, T., Joseph, R., & Åsberg Johnels, J. (2023). Discrepancy between high non-verbal intelligence and low accuracy at reading emotional expressions in the eyes reflects the magnitude of social-emotional difficulties in autism. European Archives of Psychiatry and Clinical Neuroscience, 273(3), 755–759. https://doi.org/10.1007/s00406-022-01471-z
Hammock, E. A. (2015). Developmental perspectives on oxytocin and vasopressin. Neuropsychopharmacology, 40(1), 24–42. https://doi.org/10.1038/npp.2014.120
Hendaus, M. A., Jomha, F. A., & Alhammadi, A. H. (2019). Vasopressin in the amelioration of social functioning in autism spectrum disorder. Journal of Clinical Medicine, 8(7). https://doi.org/10.3390/jcm8071061
Huang, Y., Huang, X., Ebstein, R. P., & Yu, R. (2021). Intranasal oxytocin in the treatment of autism spectrum disorders: A multilevel meta-analysis. Neuroscience & Biobehavioral Reviews, 122, 18–27. https://doi.org/10.1016/j.neubiorev.2020.12.028
Huber, D., Veinante, P., & Stoop, R. (2005). Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala. Science, 308(5719), 245–248. https://doi.org/10.1126/science.1105636
Ishii, D., Kageyama, M., & Umeda, S. (2021). Cerebral and extracerebral distribution of radioactivity associated with oxytocin in rabbits after intranasal administration: Comparison of TTA-121, a newly developed oxytocin formulation, with Syntocinon. PLoS One, 16(12), e0261451. https://doi.org/10.1371/journal.pone.0261451
Kanat, M., Spenthof, I., Riedel, A., van Elst, L. T., Heinrichs, M., & Domes, G. (2017). Restoring effects of oxytocin on the attentional preference for faces in autism. Translational Psychiatry, 7(4), e1097–e1097. https://doi.org/10.1038/tp.2017.67
Karbasi, A., Shafiezadegan Isfahani, S., Maracy, M. R., & Sabzghabaee, A. M. (2023). Effect of intranasal oxytocin combination therapy with applied behavior analysis on social impairments in pediatric’s children with autism spectrum disorder. Middle East Current Psychiatry, 30(1), 35. https://doi.org/10.1186/s43045-023-00300-w
Kasari, C., Freeman, S., & Paparella, T. (2006). Joint attention and symbolic play in young children with autism: A randomized controlled intervention study. Journal of Child Psychology and Psychiatry, 47(6), 611–620. https://doi.org/10.1111/j.1469-7610.2005.01567.x
Kato, Y., Kuwabara, H., Okada, T., Munesue, T., Benner, S., Kuroda, M., et al. (2021). Oxytocin-induced increase in N,N-dimethylglycine and time course of changes in oxytocin efficacy for autism social core symptoms. Molecular Autism, 12(1), 15. https://doi.org/10.1186/s13229-021-00423-z
Kirsch, P. (2015). Oxytocin in the socioemotional brain: Implications for psychiatric disorders. Dialogues in Clinical Neuroscience, 17(4), 463–476. https://doi.org/10.31887/DCNS.2015.17.4/pkirsch
Kitagawa, K., Matsumura, K., Baba, M., Kondo, M., Takemoto, T., Nagayasu, K., et al. (2021). Intranasal oxytocin administration ameliorates social behavioral deficits in a POGZ(WT/Q1038R) mouse model of autism spectrum disorder. Molecular Brain, 14(1), 56. https://doi.org/10.1186/s13041-021-00769-8
Kosaka, H., Okamoto, Y., Munesue, T., Yamasue, H., Inohara, K., Fujioka, T., et al. (2016). Oxytocin efficacy is modulated by dosage and oxytocin receptor genotype in young adults with high-functioning autism: A 24-week randomized clinical trial. Translational Psychiatry, 6(8), e872. https://doi.org/10.1038/tp.2016.152
Kothari, R., Skuse, D., Wakefield, J., & Micali, N. (2013). Gender differences in the relationship between social communication and emotion recognition. Journal of the American Academy of Child & Adolescent Psychiatry, 52(11), 1148–1157.e1142. https://doi.org/10.1016/j.jaac.2013.08.006
Kruppa, J. A., Gossen, A., Oberwelland Weiß, E., Kohls, G., Großheinrich, N., Cholemkery, H., et al. (2019). Neural modulation of social reinforcement learning by intranasal oxytocin in male adults with high-functioning autism spectrum disorder: A randomized trial. Neuropsychopharmacology, 44(4), 749–756. https://doi.org/10.1038/s41386-018-0258-7
Le, J., Zhang, L., Zhao, W., Zhu, S., Lan, C., Kou, J., et al. (2022). Infrequent intranasal oxytocin followed by positive social interaction improves symptoms in autistic children: A pilot randomized clinical trial. Psychotherapy and Psychosomatics, 91(5), 335–347. https://doi.org/10.1159/000524543
Lee, M. R., Wehring, H. J., McMahon, R. P., Liu, F., Linthicum, J., Verbalis, J. G., et al. (2016). Relationship of plasma oxytocin levels to baseline symptoms and symptom changes during three weeks of daily oxytocin administration in people with schizophrenia. Schizophrenia Research, 172(1), 165–168. https://doi.org/10.1016/j.schres.2016.02.014
Li, Y., Wang, Y., & Zhang, T. (2022). Fecal microbiota transplantation in autism spectrum disorder. Neuropsychiatric Disease and Treatment, 18, 2905–2915. https://doi.org/10.2147/ndt.S382571
Liang, Y., Duan, L., Xu, X., Li, X., Liu, M., Chen, H., et al. (2020). Mesenchymal stem cell-derived exosomes for treatment of autism spectrum disorder. ACS Applied Bio Materials, 3(9), 6384–6393. https://doi.org/10.1021/acsabm.0c00831
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P., et al. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. Bmj, 339, b2700. https://doi.org/10.1136/bmj.b2700
Lin, I. F., Kashino, M., Ohta, H., Yamada, T., Tani, M., Watanabe, H., et al. (2014). The effect of intranasal oxytocin versus placebo treatment on the autonomic responses to human sounds in autism: A single-blind, randomized, placebo-controlled, crossover design study. Molecular Autism, 5(1), 20. https://doi.org/10.1186/2040-2392-5-20
Linkowski, P., Geenen, V., Kerkhofs, M., Mendlewicz, J., & Legros, J. J. (1984). Cerebrospinal fluid neurophysins in affective illness and in schizophrenia. European Archives of Psychiatry and Neurological Sciences, 234(3), 162–165. https://doi.org/10.1007/bf00461555
Liu, X., Kawamura, Y., Shimada, T., Otowa, T., Koishi, S., Sugiyama, T., et al. (2010). Association of the oxytocin receptor (OXTR) gene polymorphisms with autism spectrum disorder (ASD) in the Japanese population. Journal of Human Genetics, 55(3), 137–141. https://doi.org/10.1038/jhg.2009.140
Lord, C., Elsabbagh, M., Baird, G., & Veenstra-Vanderweele, J. (2018). Autism spectrum disorder. Lancet, 392(10146), 508–520. https://doi.org/10.1016/s0140-6736(18)31129-2
Matsumoto, E., Namekawa, J., Kaneko, H., Shimomoto, T., Masuyama, M., Fujiwara, T., & Miura, D. (2019). A 6-week repeated intranasal dose toxicity study of TTA-121, a novel oxytocin nasal spray, in cynomolgus monkeys. Fundamental Toxicological Sciences, 6, 269–275. https://doi.org/10.2131/fts.6.269
Mayer, A. V., Preckel, K., Ihle, K., Piecha, F. A., Junghanns, K., Reiche, S., et al. (2022). Assessment of reward-related brain function after a single dose of oxytocin in autism: A randomized controlled trial. Biological Psychiatry Global Open Science, 2(2), 136–146. https://doi.org/10.1016/j.bpsgos.2021.10.004
Mayer, A. V., Wermter, A. K., Stroth, S., Alter, P., Haberhausen, M., Stehr, T., et al. (2021). Randomized clinical trial shows no substantial modulation of empathy-related neural activation by intranasal oxytocin in autism. Scientific Reports, 11(1), 15056. https://doi.org/10.1038/s41598-021-94407-x
Moerkerke, M., Daniels, N., Van der Donck, S., Tibermont, L., Tang, T., Debbaut, E., et al. (2023). Can repeated intranasal oxytocin administration affect reduced neural sensitivity towards expressive faces in autism? A randomized controlled trial. Journal of Child Psychology and Psychiatry. https://doi.org/10.1111/jcpp.13850
Moss, P., Mandy, W., & Howlin, P. (2017). Child and adult factors related to quality of life in adults with autism. Journal of Autism and Developmental Disorders, 47(6), 1830–1837. https://doi.org/10.1007/s10803-017-3105-5
Munesue, T., Nakamura, H., Kikuchi, M., Miura, Y., Takeuchi, N., Anme, T., et al. (2016). Oxytocin for male subjects with autism spectrum disorder and comorbid intellectual disabilities: A randomized pilot study. Frontiers in Psychiatry, 7, 2. https://doi.org/10.3389/fpsyt.2016.00002
Nowicki, S., & Duke, M. (2001). Nonverbal receptivity: The Diagnostic Analysis of Nonverbal Accuracy (DANVA). Interpersonal sensitivity: Theory and measurement, 183-198.
Nowicki, S., & Duke, M. P. (1994). Individual differences in the nonverbal communication of affect: The diagnostic analysis of nonverbal accuracy scale. Journal of Nonverbal Behavior, 18(1), 9–35. https://doi.org/10.1007/BF02169077
Ophir, A. G., Gessel, A., Zheng, D. J., & Phelps, S. M. (2012). Oxytocin receptor density is associated with male mating tactics and social monogamy. Hormones and Behavior, 61(3), 445–453. https://doi.org/10.1016/j.yhbeh.2012.01.007
Owada, K., Okada, T., Munesue, T., Kuroda, M., Fujioka, T., Uno, Y., et al. (2019). Quantitative facial expression analysis revealed the efficacy and time course of oxytocin in autism. Brain : a journal of neurology, 142(7), 2127–2136.
Parker, K. J., Oztan, O., Libove, R. A., Mohsin, N., Karhson, D. S., Sumiyoshi, R. D., et al. (2019). A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism. Science Translational Medicine, 11(491). https://doi.org/10.1126/scitranslmed.aau7356
Parker, K. J., Oztan, O., Libove, R. A., Sumiyoshi, R. D., Jackson, L. P., Karhson, D. S., et al. (2017). Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism. Proceedings of the National Academy of Sciences, 114(30), 8119–8124. https://doi.org/10.1073/pnas.1705521114
Pedersen, C. A., Ascher, J. A., Monroe, Y. L., & Prange, A. J., Jr. (1982). Oxytocin induces maternal behavior in virgin female rats. Science, 216(4546), 648–650. https://doi.org/10.1126/science.7071605
Perets, N., Hertz, S., London, M., & Offen, D. (2018). Intranasal administration of exosomes derived from mesenchymal stem cells ameliorates autistic-like behaviors of BTBR mice. Molecular Autism, 9, 57. https://doi.org/10.1186/s13229-018-0240-6
Perets, N., Oron, O., Herman, S., Elliott, E., & Offen, D. (2020). Exosomes derived from mesenchymal stem cells improved core symptoms of genetically modified mouse model of autism Shank3B. Molecular Autism, 11(1), 65. https://doi.org/10.1186/s13229-020-00366-x
Quintana, D. S., Westlye, L. T., Hope, S., Nærland, T., Elvsåshagen, T., Dørum, E., et al. (2017). Dose-dependent social-cognitive effects of intranasal oxytocin delivered with novel Breath Powered device in adults with autism spectrum disorder: A randomized placebo-controlled double-blind crossover trial. Translational Psychiatry, 7(5), e1136. https://doi.org/10.1038/tp.2017.103
Rahim, F., Toguzbaeva, K., Qasim, N. H., Dzhusupov, K. O., Zhumagaliuly, A., & Khozhamkul, R. (2023). Probiotics, prebiotics, and synbiotics for patients with autism spectrum disorder: A meta-analysis and umbrella review. Frontiers in Nutrition, 10, 1294089. https://doi.org/10.3389/fnut.2023.1294089
Ross, H. E., & Young, L. J. (2009). Oxytocin and the neural mechanisms regulating social cognition and affiliative behavior. Frontiers in Neuroendocrinology, 30(4), 534–547. https://doi.org/10.1016/j.yfrne.2009.05.004
Sasayama, D., Hattori, K., Teraishi, T., Hori, H., Ota, M., Yoshida, S., et al. (2012). Negative correlation between cerebrospinal fluid oxytocin levels and negative symptoms of male patients with schizophrenia. Schizophrenia Research, 139(1-3), 201–206. https://doi.org/10.1016/j.schres.2012.06.016
Scahill, L., Hallett, V., Aman, M. G., McDougle, C. J., Eugene Arnold, L., McCracken, J. T., et al. (2013). Brief Report: Social disability in autism spectrum disorder: Results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials. Journal of Autism and Developmental Disorders, 43(3), 739–746. https://doi.org/10.1007/s10803-012-1689-3
Schertz, H. H., & Odom, S. L. (2007). Promoting joint attention in toddlers with autism: A parent-mediated developmental model. Journal of Autism and Developmental Disorders, 37(8), 1562–1575. https://doi.org/10.1007/s10803-006-0290-z
Sena, E. S., Currie, G. L., McCann, S. K., Macleod, M. R., & Howells, D. W. (2014). Systematic reviews and meta-analysis of preclinical studies: Why perform them and how to appraise them critically. Journal of Cerebral Blood Flow and Metabolism, 34(5), 737–742. https://doi.org/10.1038/jcbfm.2014.28
Sikich, L., Kolevzon, A., King, B. H., McDougle, C. J., Sanders, K. B., Kim, S. J., et al. (2021). Intranasal oxytocin in children and adolescents with autism spectrum disorder. The New England Journal of Medicine, 385(16), 1462–1473. https://doi.org/10.1056/NEJMoa2103583
Simmons, T. C., Balland, J. F., Dhauna, J., Yang, S. Y., Traina, J. L., Vazquez, J., & Bales, K. L. (2017). Early Intranasal vasopressin administration impairs partner preference in adult male prairie voles (Microtus ochrogaster). Frontiers in Endocrinology (Lausanne), 8, 145. https://doi.org/10.3389/fendo.2017.00145
Sippel, L. M., Flanagan, J. C., Holtzheimer, P. E., Moran-Santa-Maria, M. M., Brady, K. T., & Joseph, J. E. (2021). Effects of intranasal oxytocin on threat- and reward-related functional connectivity in men and women with and without childhood abuse-related PTSD. Psychiatry Research: Neuroimaging, 317, 111368. https://doi.org/10.1016/j.pscychresns.2021.111368
Skevington, S. M., Lotfy, M., & O'Connell, K. A. (2004). The World Health Organization's WHOQOL-BREF quality of life assessment: Psychometric properties and results of the international field trial. A report from the WHOQOL group. Quality of Life Research, 13(2), 299–310. https://doi.org/10.1023/b:Qure.0000018486.91360.00
Snowdon, C. T., Pieper, B. A., Boe, C. Y., Cronin, K. A., Kurian, A. V., & Ziegler, T. E. (2010). Variation in oxytocin is related to variation in affiliative behavior in monogamous, pairbonded tamarins. Hormones and Behavior, 58(4), 614–618. https://doi.org/10.1016/j.yhbeh.2010.06.014
Stavropoulos, K. K., & Carver, L. J. (2013). Research review: Social motivation and oxytocin in autism--implications for joint attention development and intervention. Journal of Child Psychology and Psychiatry, 54(6), 603–618. https://doi.org/10.1111/jcpp.12061
Strathearn, L., Kim, S., Bastian, D. A., Jung, J., Iyengar, U., Martinez, S., et al. (2018). Visual systemizing preference in children with autism: A randomized controlled trial of intranasal oxytocin. Development and Psychopathology, 30(2), 511–521. https://doi.org/10.1017/s0954579417001018
Toolan, C., Holbrook, A., Schlink, A., Shire, S., Brady, N., & Kasari, C. (2022). Using the Clinical Global Impression scale to assess social communication change in minimally verbal children with autism spectrum disorder. Autism Research, 15(2), 284–295. https://doi.org/10.1002/aur.2638
Troyb, E., Orinstein, A., Tyson, K., Eigsti, I. M., Naigles, L., & Fein, D. (2014). Restricted and repetitive behaviors in individuals with a history of ASDs who have achieved optimal outcomes. Journal of Autism and Developmental Disorders, 44(12), 3168–3184. https://doi.org/10.1007/s10803-014-2182-y
Tural Hesapcioglu, S., Ceylan, M. F., Kasak, M., & Sen, C. P. (2020). Olanzapine, risperidone, and aripiprazole use in children and adolescents with autism spectrum disorders. Research in Autism Spectrum Disorders, 72, 101520. https://doi.org/10.1016/j.rasd.2020.101520
Turner, M. (2020). The role of drugs in the treatment of autism. Australian Prescriber, 43(6), 185–190. https://doi.org/10.18773/austprescr.2020.054
Wang, L., Dholakia, R., & Leslie, D. (2014). Use of aripiprazole and risperidone in children with autism: Effects of introducing an alternative new patented drug and debuting the first generic drug. Value in Health, 17(3), A222. https://doi.org/10.1016/j.jval.2014.03.1300
Wang, T., Shan, L., Miao, C., Xu, Z., & Jia, F. (2021). Treatment effect of bumetanide in children with autism spectrum disorder: A systematic review and meta-analysis. Frontiers in Psychiatry, 12, 751575. https://doi.org/10.3389/fpsyt.2021.751575
Watanabe, T., Abe, O., Kuwabara, H., Yahata, N., Takano, Y., Iwashiro, N., et al. (2014). Mitigation of sociocommunicational deficits of autism through oxytocin-induced recovery of medial prefrontal activity: A randomized trial. JAMA Psychiatry, 71(2), 166–175. https://doi.org/10.1001/jamapsychiatry.2013.3181
Watanabe, T., Kuroda, M., Kuwabara, H., Aoki, Y., Iwashiro, N., Tatsunobu, N., et al. (2015). Clinical and neural effects of six-week administration of oxytocin on core symptoms of autism. Brain, 138(Pt 11), 3400–3412. https://doi.org/10.1093/brain/awv249
Yamasue, H., Kojima, M., Kuwabara, H., Kuroda, M., Matsumoto, K., Kanai, C., et al. (2022). Effect of a novel nasal oxytocin spray with enhanced bioavailability on autism: A randomized trial. Brain, 145(2), 490–499. https://doi.org/10.1093/brain/awab291
Yamasue, H., Okada, T., Munesue, T., Kuroda, M., Fujioka, T., Uno, Y., et al. (2020). Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: A randomized clinical trial. Molecular Psychiatry, 25(8), 1849–1858. https://doi.org/10.1038/s41380-018-0097-2
Yatawara, C. J., Einfeld, S. L., Hickie, I. B., Davenport, T. A., & Guastella, A. J. (2016). The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: A randomized clinical crossover trial. Molecular Psychiatry, 21(9), 1225–1231. https://doi.org/10.1038/mp.2015.162
Yoshimura, Y., Kikuchi, M., Hiraishi, H., Hasegawa, C., Hirosawa, T., Takahashi, T., et al. (2018). Longitudinal changes in the mismatch field evoked by an empathic voice reflect changes in the empathy quotient in autism spectrum disorder. Psychiatry Research: Neuroimaging, 281, 117–122. https://doi.org/10.1016/j.pscychresns.2018.05.003
Zhang, R., Xu, X. J., Zhang, H. F., Han, S. P., & Han, J. S. (2017). The role of the oxytocin/arginine vasopressin system in animal models of autism spectrum disorder. Advances in Anatomy, Embryology, and Cell Biology, 224, 135–158. https://doi.org/10.1007/978-3-319-52498-6_8
Zhou, B., Yan, X., Yang, L., Zheng, X., Chen, Y., Liu, Y., et al. (2022). Effects of arginine vasopressin on the transcriptome of prefrontal cortex in autistic rat model. Journal of Cellular and Molecular Medicine, 26(21), 5493–5505. https://doi.org/10.1111/jcmm.17578
Acknowledgements
The authors would like to thank all participants of the research.
Author information
Authors and Affiliations
Contributions
FR and NHQ developed the concept, conducted the data analysis, wrote, and revised the first draft of the manuscript. TK and FK developed the concept, contributed to the draft review, editing, and validation. KD, AT, and KEI developed the concept participated in language editing.
Corresponding author
Ethics declarations
Ethics Approval
The article is comprehensive in its consideration of ethical concepts. The research’s goals and methodology were explained to the participants. Participants were also told that their information would be kept private, that they would be allowed to withdraw from the study at any time, and that they would be given access to the study’s findings if they so choose. The ethics committee gave the study the all-clear.
Conflict of Interest
The authors declare no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
ESM 1
(DOCX 582 kb)
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Rahim, F., Karlygash, T., Qasim, N.H. et al. Intranasal Oxytocin for Patients With Autism Spectrum Disorder: A Comprehensive Meta-Analysis of Preclinical and Clinical Studies. Rev J Autism Dev Disord (2024). https://doi.org/10.1007/s40489-024-00428-3
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s40489-024-00428-3